An experimental vaccine developed at Johns Hopkins has shown promise in generating lasting immune responses against pancreatic cancer in people at high risk. In an early-stage clinical trial, 90% of participants developed a significant immune response to mutant KRAS, supporting further research into vaccine-based cancer prevention.
